Biocon to Produce Devices for Insulin Portfolio
Biocon opens a facility to manufacture devices for its insulin portfolio. The facility is said to be spread over 10,000 […]
Say something
Tags: Biocon, biology, diabetes, Diabetes mellitus type 1, Eli Lilly and Company, Endocrine system, Health/Medical/Pharmaceuticals, healthcare, India, insulin, Insulin glargine, insulin products, insulin-dependent diabetes, Kiran Mazumdar-Shaw, media reports, medicine, pen like delivery devices, Peptide hormones, Recombinant proteins
NHS urged to work alongwith pharma industry
New guidelines, issued by the Department of Health, call for more partnerships between the NHS and drug companies, stressing they should be “of mutual benefit with the principal beneficiary being the patient”.
-
-
Flipkart Health+ App Launched
06-04-2022
